Cargando…

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis

BACKGROUND & AIMS: With the rising prevalence of non‐alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) non‐invasive tools obtaining pathomechanistic insights to improve risk stratification are urgently needed. We therefore explored high‐ and ultra‐high‐field magnetic resonance spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Traussnigg, Stefan, Kienbacher, Christian, Gajdošík, Martin, Valkovič, Ladislav, Halilbasic, Emina, Stift, Judith, Rechling, Christian, Hofer, Harald, Steindl‐Munda, Petra, Ferenci, Peter, Wrba, Fritz, Trattnig, Siegfried, Krššák, Martin, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Metabolic Liver Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638103/ https://www.ncbi.nlm.nih.gov/pubmed/28544208 http://dx.doi.org/10.1111/liv.13451

Ejemplares similares

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
por: Traussnigg, Stefan, et al.
Publicado: (2020)

Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease
por: Paternostro, Rafael, et al.
Publicado: (2021)

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
por: Brennan, Paul N, et al.
Publicado: (2022)

In Vivo (1)H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T
por: Gajdošík, Martin, et al.
Publicado: (2020)

The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Karim, Gres, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease: a practical approach to treatment
por: Dyson, J K, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
por: Dyson, Jessica K, et al.
Publicado: (2014)

Detection and Alterations of Acetylcarnitine in Human Skeletal Muscles by 1H MRS at 7 T
por: Klepochová, Radka, et al.
Publicado: (2017)

Salford alcohol assertive outreach team: a new model for reducing alcohol-related admissions
por: Hughes, Neill R, et al.
Publicado: (2013)

Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease
por: Neilson, Laura Jane, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls
por: Hallsworth, Kate, et al.
Publicado: (2015)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency
por: Luger, Maria, et al.
Publicado: (2016)

Current treatment of non‐alcoholic fatty liver disease
por: Paternostro, Rafael, et al.
Publicado: (2022)

Alcohol care teams: where are we now?
por: Moriarty, Kieran John
Publicado: (2019)

Non‐invasive diagnosis of cirrhosis and long‐term disease monitoring by transient elastography in patients with Wilson disease
por: Paternostro, Rafael, et al.
Publicado: (2020)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
por: Schattenberg, Jörn M., et al.
Publicado: (2021)

In-vivo(31)P-MRS of skeletal muscle and liver: A way for non-invasive assessment of their metabolism
por: Valkovič, Ladislav, et al.
Publicado: (2017)

Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma
por: Nardo, Alexander D., et al.
Publicado: (2020)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study
por: Heyes, Cathy M., et al.
Publicado: (2016)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma
por: Ramai, Daryl, et al.
Publicado: (2021)

Feasibility and repeatability of localized (31)P‐MRS four‐angle saturation transfer (FAST) of the human gastrocnemius muscle using a surface coil at 7 T
por: Tušek Jelenc, Marjeta, et al.
Publicado: (2016)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
por: Pavlides, Michael, et al.
Publicado: (2017)

Insights Into the Experience of Liver Transplant Recipients With Alcoholic Liver Disease: A Descriptive Qualitative Study
por: Hochheimer, Martin, et al.
Publicado: (2019)

Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)()
por: Jha, Pooja, et al.
Publicado: (2014)

Endothelial dysfunction in patients with non-alcoholic steatohepatitis
por: Onal, Ibrahim Koral
Publicado: (2014)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management
por: Salomone, Federico, et al.
Publicado: (2015)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
por: Habig, Gregory, et al.
Publicado: (2021)

Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
por: Rios, Rafael S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f9sh8gnp4bvmgs20v48u70b664